Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute, France | OTHER_GOV |
| Sciensano | OTHER_GOV |
| University Hospital, Angers | OTHER_GOV |
| Angers University |
Not provided
Not provided
Not provided
The cervical cancer screening coverage remains moderate (60%) in France. The aim of the study is to evaluate the efficacy of two experimental invitation strategies (offer of urine or vaginal self-sampling kits) to reach under-screened populations and compare them with the current invitation strategy in rural departments (low medical density and low participation rate) in France.
The study is a randomised controlled trial with three arms: a control arm (conventional invitation letter) and two experimental arms (mailing of a urine or vaginal self-sampling kit). The target population includes women aged 30-65 years, who had no screening test recorded since more than four years and who did not respond to an invitation letter within twelve months before. The primary outcome measure is the participation rate in each arm.
A team of psychologists will also investigate attitudes and experiences by semi-structured/focus-group interviews with voluntary CapU4 participants and with health professionals.
CapU4 will identify effective strategies to reach women not responding to current screening invitations and will generate information about acceptance of self-sampling among women and health professionals.
Research question: does the offer of self-sampling kits result in higher attendance to cervical cancer screening compared to sending invitation letters which recommend women to contact a health professional for taking a cervical specimen?
Systematic reviews indicate that Human Papillomavirus (HPV) testing on vaginal specimens taken by the woman her-self is as accurate to detect cervical precancer as HPV testing of cervical specimens collected by a clinician, under the condition that a validated polymerase chain reaction (PCR)-based HPV assay is used. Similar results are shown from recent studies where HPV testing was performed on first-void urine collected with an appropriate device and transport medium. A recent meta-analysis of randomised trials showed higher response rates when under-screened women receive a self-sampling kit at home compared to traditional invitation or reminder letters. However, the absolute participation rates are highly variable among studies. Whereas qualitative research indicates that women prefer collection of urine rather than a vaginal self-sample, no data are available that the offer of urine kits would result in higher participation among women who do not participate regularly in cervical cancer screening.
Objectives:
Trial design:
1:1:1 randomised population-based participation trial, with 2 experimental and 1 control arm, with in each arm a 1:1 sub-randomisation with subgroup A receiving a questionnaire and subgroup B receiving no questionnaire.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| control | No Intervention | The control arm corresponds to women receive a conventional invitation letter sent by post to the home address of eligible women recommending them to make an appointment to a doctor or a midwife for the collection of a cervical specimen. | |
| vaginal self-sampling | Experimental | eligible women receive at their home address a vaginal self-sampling kit in addition to the conventional invitation letter |
|
| urinary self-sampling | Experimental | eligible women receive at their home address a urine collection kit in addition to the conventional invitation letter |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| self-sampling | Diagnostic Test | eligible women receive at their home address a self-sampling kit in addition to the conventional invitation letter |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of participation in each arm (%) | (number of responding / number of invited) | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Rate of participation (%) | (number of responding / number of invited). Contrast in participation between the 2 experimental arms | 6 months |
| Rate of participation (%) with questionnaire or not | (number of responding / number of invited). Contrast in participation between women that received a questionnaire or not |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CRCDC Pays de la Loire | Angers | France |
Not provided
| OTHER |
The study is a randomised controlled trial with three arms: a control arm (conventional invitation letter) and two experimental arms (mailing of a urine or vaginal self-sampling kit).
Not provided
Not provided
Not provided
Not provided
| 6 months |
| Rate of screen test positivity (%) | Virological result. presence of high-risk HPV | 24 months |
| Percentage of women screened positive with adherence to gynecological follow-up | gynecological follow-up (cytological results) | 24 months |
| Impact of age on the participation (rate of participation %) | age | 6 months |
| Impact of age on the adherence to gynecological follow-up (% of women) | age | 24 months |
| Impact of reimbursement status on the participation (rate of participation %) | reimbursement status (benefit or not from supplementary universal health care coverage) | 6 months |
| Impact of reimbursement status on the adherence to gynecological follow-up (% of women) | reimbursement status (benefit or not from supplementary universal health care coverage) | 24 months |
| Impact of geographical area on the participation (rate of participation %) | geographical area (including the deprivation index corresponding with the statistical sector where the woman is domiciled) | 6 months |
| Impact of geographical area on the adherence to gynecological follow-up (% of women) | geographical area (geographical area (including the deprivation index corresponding with the statistical sector where the woman is domiciled) | 24 months |
| Obstacles and levers emerging from the speech of the women participating in the research (thematic analysis) | thematic analysis integrating a specific focus on the indicators identified in previous studies (e.g. lack of time, discomfort with regard to the location or bad experience encountered during another type of examination, etc.). | 24 months |
| Obstacles and levers emerging from the speech of the women participating in the research (categorical analysis) | categorical analysis based on Linguistic Inquiry and Word count which allows, among other things, to automatically categorise positive or negative emotions related to themes for example associated with the disease or beliefs | 24 months |
| Obstacles and levers emerging from the speech of the health professionals participating in the research (thematic analysis) | thematic analysis integrating a specific focus on the indicators identified in previous studies (e.g. lack of time, discomfort with regard to the location or bad experience encountered during another type of examination, etc.). | 24 months |
| Obstacles and levers emerging from the speech of the health professionals participating in the research (categorical analysis) | categorical analysis based on Linguistic Inquiry and Word count which allows, among other things, to automatically categorise positive or negative emotions related to themes for example associated with the disease or beliefs | 24 months |
| ID | Term |
|---|---|
| D002583 | Uterine Cervical Neoplasms |
| ID | Term |
|---|---|
| D014594 | Uterine Neoplasms |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D002577 | Uterine Cervical Diseases |
| D014591 | Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
Not provided
Not provided